Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie J B Vos

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Neurology|March 8, 2019
The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individualsStephanie J B Vos, Ranjan Duara
The Lancet. Neurology|September 13, 2013
Preclinical Alzheimer's disease criteriaAnne M Fagan, Stephanie J B Vos
The Lancet. Neurology|November 25, 2015
Alzheimer's disease biomarker statesStephanie J B Vos, Anne M Fagan
Journal of Alzheimer'S Disease : JAD|June 6, 2018
Preclinical Alzheimer's Disease: Implications for Refinement of the ConceptStephanie J B Vos, Pieter Jelle Visser
Nature Reviews. Neurology|May 9, 2024
The clinical importance of suspected non-Alzheimer disease pathophysiologyStephanie J B Vos, Aurore Delvenne, Clifford R Jack, et al.
Journal of Alzheimer'S Disease : JAD|May 30, 2026
Longitudinal amyloid PET changes by cerebrospinal fluid amyloid and tau profiles in individuals with normal cognition: Role of <i>APOE</i> ε4Marianna Rizzo, Julie E Oomens, Willemijn J Jansen, et al.
Neurobiology of Aging|June 19, 2016
NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkersStephanie J B Vos, Brian A Gordon, Yi Su, et al.
Journal of the American Medical Directors Association|March 2, 2020
Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical CharacteristicsOlin Janssen, Stephanie J B Vos, Ron Handels, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 6, 2019
Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's diseaseIsabelle Bos, Stephanie J B Vos, Suzanne E Schindler, et al.
Plos One|June 25, 2014
Variability of CSF Alzheimer's disease biomarkers: implications for clinical practiceStephanie J B Vos, Pieter Jelle Visser, Frans Verhey, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Neurology|March 8, 2019
The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individualsStephanie J B Vos, Ranjan Duara
The Lancet. Neurology|September 13, 2013
Preclinical Alzheimer's disease criteriaAnne M Fagan, Stephanie J B Vos
The Lancet. Neurology|November 25, 2015
Alzheimer's disease biomarker statesStephanie J B Vos, Anne M Fagan
Journal of Alzheimer'S Disease : JAD|June 6, 2018
Preclinical Alzheimer's Disease: Implications for Refinement of the ConceptStephanie J B Vos, Pieter Jelle Visser
Nature Reviews. Neurology|May 9, 2024
The clinical importance of suspected non-Alzheimer disease pathophysiologyStephanie J B Vos, Aurore Delvenne, Clifford R Jack, et al.
Journal of Alzheimer'S Disease : JAD|May 30, 2026
Longitudinal amyloid PET changes by cerebrospinal fluid amyloid and tau profiles in individuals with normal cognition: Role of <i>APOE</i> ε4Marianna Rizzo, Julie E Oomens, Willemijn J Jansen, et al.
Neurobiology of Aging|June 19, 2016
NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkersStephanie J B Vos, Brian A Gordon, Yi Su, et al.
Journal of the American Medical Directors Association|March 2, 2020
Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical CharacteristicsOlin Janssen, Stephanie J B Vos, Ron Handels, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 6, 2019
Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's diseaseIsabelle Bos, Stephanie J B Vos, Suzanne E Schindler, et al.
Plos One|June 25, 2014
Variability of CSF Alzheimer's disease biomarkers: implications for clinical practiceStephanie J B Vos, Pieter Jelle Visser, Frans Verhey, et al.
Pageof 8